AUSTRALIA'S #1 ONLINE CPD EDUCATION PLATFORM

QI Programs

Clinical audits are only available to Australian-registered GPs.

ThinkGP’s range of clinical audits have been designed to arm GPs with the tools they need to excel, benchmarking standards of care to the highest level. With step-by-step guides, on the job development and reflective learning, our clinical audits are centred on aiding GPs to provide quality patient care and outcomes. Whether newly qualified or practicing for years, a clinical audit will ensure you are on track to deliver optimal patient outcomes and keep you up to date with best practice across a range of therapeutic areas. Each activity has a reflective learning component to help solidify and embed learnings.

Strong Steps program: Stepwise approach to identification and prevention of osteoporotic fracture

Clinical audit | RACGP: 40pts | ACRRM: 7hrs | GPs only

By 2022, it is estimated that 6.2 million Australians older than 50 years of age will have osteoporosis or osteopenia, placing them at high risk of minimal trauma fracture. This program aims to support identification, evaluation and treatment of patients at high risk of osteoporotic fracture.

Identifying ID clinical audit: Screening and managing your patients with iron deficiency

Clinical audit | RACGP: 40pts | ACRRM: 6hrs | GPs only

Iron deficiency (ID) is the most common nutritional deficiency in Australia. Management is based on initiation of iron therapy to correct ID, and concurrent diagnosis and management of the underlying cause. This clinical audit aims to improve the management of patients with iron deficiency following oral or IV iron supplementation.

IN Control clinical audit: INsulin INitiation and INtensification to avoid clinical INertia

Clinical audit | RACGP: 40pts | ACRRM: 6hrs | GPs only

Timely intensification of glucose-lowering medications to achieve target HbA1c is a key aspect of type 2 diabetes management. This program aims to support initiation or intensification of insulin therapy for patients who are currently not at their target HbA1c.
RELX Group plc